The future of imaging: Developing the tools for monitoring response to therapy in oncology: The 2009 Sir James MacKenzie Davidson Memorial lecture

British Journal of Radiology

Volumn 83, Issue 994, 2010, Pages 814-822

  Aboagye, Eric O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CHOLINE; D4 CHOLINE F 18; DEUTERIUM; FLUORO [1,2 2 H2]CHOLINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; IMAGE QUALITY; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO CULTURE; MEDICAL RESEARCH; ONCOLOGY; REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION ONCOLOGY; RADIOPHARMACEUTICALS;

EID: 77957658627     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/77317821     Document Type: Review

References (77)

1. Aboagye E. The use of imaging to accelerate drug development. Drug Discov Today 2002;7:706-7.
2. Aboagye EO. Imaging in drug development. Clin Adv Hematol Oncol 2006;4:902-4.
3. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 2006;98:580-98.
4. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009;50 Suppl 1:97S-105S.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
6. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
7. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007;4:631-51.
8. Gagnon MK, Hausner SH, Marik J, Abbey CK, Marshall JF, Sutcliffe JL. High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci U S A 2009;106:17904-9.
9. 11C]Carbon monoxide, a versatile and useful precursor in labelling chemistry for PET-ligand development. J Labelled Comp Radiopharm 2007;50:794-810.
10. Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010;49:1364-76.
11. Smith G, Glaser M, Perumal M, Nguyen QD, Shan B, Arstad E, et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F] fluoroethylazide. J Med Chem 2008;51:8057-67.
12. Elsinga PH. Radiopharmaceutical chemistry for positron emission tomography. Methods 2002;27:208-17.
13. Chu W, Zhang J, Zeng C, Rothfuss J, Tu Z, Chu Y, et al. N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies. J Med Chem 2005;48:7637-47.
14. Podichetty AK, Faust A, Kopka K, Wagner S, Schober O, Schafers M, et al. Fluorinated isatin derivatives. Part 1: synthesis of new N-substituted (S)-5-[1-(2-methoxymethyl-pyrrolidinyl)sulfonyl]isatins as potent caspase-3 and -7 inhibitors. Bioorg Med Chem 2009;17:2680-8.
15. Podichetty AK, Wagner S, Schroer S, Faust A, Schafers M, Schober O, et al. Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis. J Med Chem 2009;52:3484-95.
16. Smith G, Nguyen QD, Aboagye EO. Translational imaging of apoptosis. Anticancer Agents Med Chem 2009;9:958-67.
17. Chipuk JE, Green DR. Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 2005;6:268-75.
18. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
19. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med 2008;49 Suppl 2:81S-95S.
20. Collingridge DR, Glaser M, Osman S, Barthel H, Hutchinson OC, Luthra SK, et al. In vivo, selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003;89:1327-33.
21. Grierson JR, Yagle KJ, Eary JF, Tait JF, Gibson DF, Lewellen B, et al. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjug Chem 2004;15:373-9.
22. Damianovich M, Ziv I, Heyman SN, Rosen S, Shina A, Kidron D, et al. ApoSense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis. Eur J Nucl Med Mol Imaging 2006;33:281-91.
23. 131I-labeled peptides as caspase substrates for apoptosis imaging. J Nucl Med 2005;46:1066-74.
24. Aulabaugh A, Kapoor B, Huang X, Dollings P, Hum WT, Banker A, et al. Biochemical and biophysical characterization of inhibitor binding to caspase-3 reveals induced asymmetry. Biochemistry 2007;46:9462-71.
25. Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, et al. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem 2000;275:16007-14.
26. Glaser M, Arstad E. "Click labelling" with 2-[18f] fluoroethylazide for positron emission tomography. Bioconjug Chem 2007;18:989-93.
27. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 2009;106:16375-80.
28. Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001;61:4937-41.
29. Dolle F. Fluorine-18-labelled fluoropyridines: advances in radiopharmaceutical design. Curr Pharm Des 2005;11:3221-35. (Pubitemid 41300773)
30. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000;355:2125-31.
31. Chen CA, Sieburth SM, Glekas A, Hewitt GW, Trainor GL, Erickson-Viitanen S, et al. Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. Chem Biol 2001;8:1161-6.
32. Fowler JS, Wolf AP, MacGregor RR, Dewey SL, Logan J, Schlyer DJ, et al. Mechanistic positron emission tomography studies: demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-deprenyl in living baboon brain. J Neurochem 1988;51:1524-34.
33. van Dyck CH, Soares JC, Tan PZ, Staley JK, Baldwin RM, Amici LA, et al. Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med Biol 2000;27:715-22.
34. Leyton J, Smith G, Zhao Y, Perumal M, Nguyen QD, Robins E, et al. [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. Cancer Res 2009;69:7721-8.
35. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8; discussion 38-9.
36. Li MM, Rybalov M, Haider MA, de Jong IJ. Does computed tomography or positron emission tomography/computed tomography contribute to detection of small focal cancers in the prostate? J Endourol 2010;24:693-700.
37. 11C-choline PET/CT. J Nucl Med 2006;47:1249-54.
38. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
39. Contractor KB, Kenny LM, Stebbing J, Al-Nahhas A, Palmieri C, Sinnett D, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res 2009;15:5503-10.
40. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res 70;2126-35.
41. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007;8:889-97.
42. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
43. Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F] fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 2009;11:343-55.
44. Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257-63.
45. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006;66:8558-64.
46. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
47. Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 1991;11:2538-46.
48. Sutterluety H, Bartl S, Karlseder J, Wintersberger E, Seiser C. Carboxy-terminal residues of mouse thymidine kinase are essential for rapid degradation in quiescent cells. J Mol Biol 1996;259:383-92.
49. Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 2004;24:514-26.
50. Li CL, Lu CY, Ke PY, Chang ZF. Perturbation of ATP-induced tetramerization of human cytosolic thymidine kinase by substitution of serine-13 with aspartic acid at the mitotic phosphorylation site. Biochem Biophys Res Commun 2004;313:587-93.
51. Chang ZF, Huang DY, Chi LM. Serine 13 is the site of mitotic phosphorylation of human thymidine kinase. J Biol Chem 1998;273:12095-100.
52. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurzinger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31.
53. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104-12.
54. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005;46:371-80.
55. Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47:1612-21.
56. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82.
57. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008;14:2049-55. (Pubitemid 351551115)
58. Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK, et al. Kinetic analysis of 3′-deoxy-3′-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med 2009;50:1028-35.
59. Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, et al. A simplified analysis of [F-18]3′-deoxy-3 ′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 2005;32:1269-75.
60. Kenny LM, Contractor KB, Stebbing J, Al-Nahhas A, Palmieri C, Shousha S, et al. Altered tissue 3′-deoxy-3′-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res 2009;15:6649-57.
61. Pillai RG, Forster M, Perumal M, Mitchell F, Leyton J, Aibgirhio FI, et al. Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 2008;68:3827-34.
62. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
63. Barthel H, Price P, Aboagye EO. Small-animal imaging of tumour proliferation with PET. Lancet Oncol 2004;5:100. (Pubitemid 38145892)
64. Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Cancer Res 2006;66:7621-9.
65. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10.
66. Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, et al. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography imaging. Cancer Res 2006;66:9178-85.
67. Leyton J, Perumal M, Dhaliwal H, Latigo J, Aboagye EO. 3′-Deoxy-3′-[18F]fluorothymidine and 2-[18F]fluoro-2-deoxy-D-glucose as markers of response to cisplatin therapy in vivo. Br J Cancer 2004;91:S45.
68. Leyton J, Smith G, Lees M, Perumal M, Nguyen QD, Aigbirhio FI, et al. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 2008;7:3112-21.
69. Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, et al. 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007;67:11463-9.
70. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47.
71. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.
72. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-21.
73. Pio BS, Park CK, Pietras R, Hsueh W-A, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[18F]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36.
74. Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging 2007;34:1003-11.
75. de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3′-deoxy-3′- fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009;36:389-95.
76. Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, et al. Analysis and reproducibility of 3′-Deoxy-3′-[18F] fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4463-8.
77. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7. (Pubitemid 29523568)